NCT06121518View on ClinicalTrials.gov

Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy Versus D064 or D702 Monotherapy

PHASE3CompletedINTERVENTIONAL
Enrollment

235

Participants

Timeline

Start Date

July 31, 2023

Primary Completion Date

March 22, 2024

Study Completion Date

March 26, 2024

Conditions
Essential Hypertension
Interventions
DRUG

D064 and D702, QD

Experimental Group Subjects assigned to this group are treated with D064, D702

DRUG

D064 and Placebo of D702, QD

Comparator Group Subjects assigned to this group are treated with D064, placebo of D702

DRUG

Placebo of D064 and D702, QD

Comparator Group Subjects assigned to this group are treated with D702, placebo of D064

Trial Locations (1)

04763

Hanyang University Seoul Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY